Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
02/2010
02/10/2010EP2150249A2 Use of benzo-fused heterocycle sulfamide derivatives for the treatment of migraine
02/10/2010EP2150246A1 Compositions and methods for treatment of psychiatric disorders
02/10/2010EP2150117A1 Methods and compositions for mitochondrial replacement therapy
02/10/2010EP2150115A1 Cyclopropyl pyrrolidine orexin receptor antagonists
02/10/2010EP1583748B1 Process for the preparation of 1,2-dichloroethane free crystals of zonisamide and the highly pure crystals of zonisamide
02/10/2010EP1490365B1 Azaindoles as inhibitors of c-jun n-terminal kinases
02/10/2010CN101643470A Alkyl ether derivatives or salts thereof
02/10/2010CN100588647C Crystalline solid form of (2s-5z)-2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid
02/10/2010CN100588398C Substantially pure solid form of the enol tautomer of 3-indolylpyruvic acid for use in the treatment of central nervous system disturbances
02/10/2010CN100588395C Analgesic and anti-inflammatory compositions containing cox-2 inhibitors
02/09/2010US7659407 Pharmaceutical compounds
02/09/2010US7659402 use as pain relievers, gastrointestinal disorders; 2-Amino-3-aryl-1-[3-((hetero)aryl)piperidin-1-yl]-propan-1-one compounds
02/09/2010US7659387 Transgenic mammals introduced a Period 1 promoter that confers rhythmical expression
02/09/2010US7659370 Nervous system protein for use in treatment and prevention of nervous system and seizure disorders
02/09/2010US7659303 Reduce tumor necrosis factor; phosphodiesterase inhibitor; antiinflammatory agents; anticancer agents; antidepressants; skin diosrders
02/09/2010US7659302 Methods of using (+)-2-[1-(3-ethoxy-4 methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione
02/09/2010US7659286 N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide
02/09/2010US7659285 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
02/09/2010US7659282 Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
02/09/2010US7659272 N-[phenyl or heteroaryl carbonoyl pyridyl] arylsulfonamides; antiinflammatory, antianaphylactic agents; transplant rejection, gastointestinal, respriatory system and skin disorders
02/09/2010US7659269 Substituted indolealkanoic acids
02/09/2010US7659267 2-(3-cyanophenyl)-4H-1,3-benzothiazin-4-one; cardiovascular, bone or joint diseases, infectious, inflammatory, kidney diseases; safe and good effects of cell death inhibition, Migration Inhibitory Factor (MIF) binding
02/09/2010US7659255 Methods of inhibiting glutamate receptors by administering the tripeptide KDI
02/09/2010US7658939 Inert core, first layer comprising naltrexone, nalmefene or salts; and second hydrophobic layer; pain treatment
02/09/2010US7658926 Autologous T-cell vaccines materials and methods
02/09/2010US7658917 A beta aggregation core domain and a modifying group coupled thereto such that the compound alters the aggregation or inhibits the neurotoxicity of natural beta amyloid peptides when contacted with the peptides.
02/09/2010CA2663141C Creatine pyroglutamic acid salts and methods for their production and use in individuals
02/09/2010CA2614926C Crystal modification c of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic
02/09/2010CA2613061C Device for transdermal electrotransport delivery of fentanyl and sufentanil
02/09/2010CA2484954C 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as vla-4 inhibitors
02/09/2010CA2483597C New pharmaceutical compositions containing flibanserin polymorph a
02/09/2010CA2440760C Substituted pyrazolopyrimidines and thiazolopyrimidines used as analgesics
02/09/2010CA2439593C Heterocyclic compounds for aging-related and diabetic vascular complications
02/09/2010CA2438704C Substituted propane-1,3-diamine derivatives and the pharmaceutical use thereof
02/09/2010CA2437505C Isoxazoline derivatives as anti-depressants
02/09/2010CA2431079C Method and composition for the treatment of diabetic neuropathy
02/09/2010CA2418224C Pharmaceutical composition
02/09/2010CA2413061C Serine protease inhibitors
02/09/2010CA2409975C Blister package for topiramate tablets
02/09/2010CA2386297C Bicyclic amino acids as pharmaceutical agents
02/09/2010CA2378976C Method of controlling body temperature while reducing shivering
02/09/2010CA2354762C Novel therapeutic application of low molecular weight heparin
02/09/2010CA2338546C Particle-forming compositions containing fused pyrrolocarbazoles
02/09/2010CA2308274C Methods for modulating macrophage proliferation using polyamine analogs
02/09/2010CA2294276C Branched chain fatty acids, their derivatives and use in the treatment of central nervous system disorders
02/09/2010CA2294274C Compositions and methods for reversibly increasing permeability of biomembranes
02/09/2010CA2274201C Di-or triaza-spiro[4,5]decane derivatives
02/09/2010CA2218369C Transdermal electrotransport delivery of fentanyl and sufentanil
02/04/2010WO2010014739A2 Heterocyclic modulators of tgr5
02/04/2010WO2010014613A2 Treating various disorders using trkb agonists
02/04/2010WO2010014585A1 Pkc-activating compounds for the treatment of neurodegenerative diseases
02/04/2010WO2010014280A1 Pyrazinone modulator of corticotropin-releasing factor receptor activity
02/04/2010WO2010014229A1 Buprenorphine analogs
02/04/2010WO2010014025A1 Administration regime for nitrocatechols
02/04/2010WO2010013794A1 Spiroaminodihydrothiazine derivatives
02/04/2010WO2010013762A1 Metastin derivative and use thereof
02/04/2010WO2010013595A1 (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
02/04/2010WO2010013495A1 Pharmaceutical composition containing highly purified botulinum neurotoxin therapeutic agent as active ingredient, and use thereof
02/04/2010WO2010013494A1 Pharmaceutical composition comprising botulinum neurotoxin preparation incapable of being synaptically transported, and use thereof
02/04/2010WO2010013302A1 Spiroaminodihydrothiazine derivative
02/04/2010WO2010013254A2 Withania somnifera plant extract and method of preparation thereof
02/04/2010WO2010013242A1 Substituted pyridoxine-lactam carboxylate salts
02/04/2010WO2010013168A1 3',6-substituted indirubins and their biological applications
02/04/2010WO2010013050A1 Process for the preparation of o-desmethylvenlafaxine
02/04/2010WO2010013048A1 Polymorphic form of rasagiline mesylate
02/04/2010WO2010012964A2 Thiophene-2-carboxamide derivatives, preparation thereof and therapeutic use thereof
02/04/2010WO2010012904A2 Novel cholest-4-en-3-one oxime derivatives, pharmaceutical compositions containing same, and preparation method
02/04/2010WO2010012817A2 5ht7 receptor ligands and compositions comprising the same
02/04/2010WO2010012812A1 Benzazepines and benzazocines as sigma-receptor ligandes
02/04/2010WO2010012806A2 Substituted indole sulfonamide compounds, their preparation and use as medicaments
02/04/2010WO2010012789A1 1,6-dihydro-2h-3-oxa-6-aza-as-indacene compounds
02/04/2010WO2010012758A1 Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists
02/04/2010WO2010012749A1 Immunotherapy compositions for the treatment and prevention of amyloidosis
02/04/2010WO2010012620A1 Pyrrolidin-3-ylmethyl-amine as orexin antagonists
02/04/2010WO2010012611A1 Compound with serotoninergic activity, process for preparing it and pharmaceutical composition comprising it
02/04/2010WO2010012506A1 Cannabinoids for use in treating or preventing cognitive impairment and dementia
02/04/2010WO2010012399A1 Indolylamides as modulators of the ep<sb>2</sb> receptor
02/04/2010WO2010012398A1 Substituted pyridines, and use thereof as gsk3 inhibitors
02/04/2010WO2010012121A1 Aralkyl substituted piperidine or piperazine derivatives and their use for treating schizophrenia
02/04/2010WO2010012043A1 Methods and compositions
02/04/2010WO2009149258A3 Crystalline form of 6-[(4s)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
02/04/2010WO2009090227A3 PEPTIDES HAVING BINDING AFFINITY TO AN ANTIBODY WHICH RECOGNIZES AN EPITOPE ON AN α1 LOOP 2 OR β2 LOOP 1 OF AN ADRENORECEPTOR
02/04/2010WO2008132710A3 Pharmaceutical nimodipine compositions
02/04/2010WO2008121859A8 Methods of using tricyclic compounds in treating sodium channel-mediated diseases or conditions
02/04/2010US20100031377 Prevention and treatment of synucleinopathic and amyloidogenic disease
02/04/2010US20100029771 Treatment of addictive disorders
02/04/2010US20100029770 Methods of treating mental retardation, down's syndrome, fragile X syndrome and autism
02/04/2010US20100029766 Blends Comprising a Substituted Fatty Acid or a Derivative Thereof
02/04/2010US20100029758 Derivatives of isoflavones
02/04/2010US20100029744 Methods for Alzheimer's Disease Treatment and Cognitive Enhancement
02/04/2010US20100029741 Fused heterocycles
02/04/2010US20100029740 Azabicyclic compounds as serotonin, dopamine and norepinephrine re-uptake inhibitors
02/04/2010US20100029739 Use of a combination of hypothermia inducing drugs
02/04/2010US20100029738 Bicyclic Tetrahydropyrrole Compounds
02/04/2010US20100029729 Compounds
02/04/2010US20100029728 Phosphodiesterase inhibitors
02/04/2010US20100029724 Screening method
02/04/2010US20100029723 Methods and compositions for reduction of side effects of therapeutic treatments
02/04/2010US20100029719 Arylsulfonamide derivatives as c-jun-n-terminal kinases (jnk's) inhibitors
02/04/2010US20100029717 Alkylsulphonamide Quinolines
1 ... 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 ... 1833